 Hepion Pharmaceuticals Inc NASDAQ: HEPA stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis NASH trial. Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes. 